Paper6325001
Phase I trial of N-methylformamide.
McVie JG and 3 others. Cancer Treat Rep, 1984. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. Phase I trial of N-methylformamide. Papers, record 6325001. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6325001
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Formamides | Major topic |
| Neoplasms | Major topic |
| Adult | |
| Aged | |
| Alkaline Phosphatase | |
| Anorexia | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Hyperbilirubinemia | |
| Liver | |
| Male | |
| Middle Aged | |
| Nausea | |
| Peripheral Nervous System Diseases |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 12888809 | Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. | Br J Cancer | 2003 | https://conductscience.org/library/papers/12888809 | PubMed |
| 11561680 | N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial. | Invest New Drugs | 2001 | https://conductscience.org/library/papers/11561680 | PubMed |
| 3948299 | The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3948299 | PubMed |
| 3654153 | Phase II trial of N-methylformamide in advanced head and neck cancer. | Invest New Drugs | 1987 | https://conductscience.org/library/papers/3654153 | PubMed |
| 3552281 | N-methyl antitumour agents. A distinct class of anticancer drugs? | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3552281 | PubMed |
| 3196150 | Comparative hepatotoxicity and metabolism of N-methylformamide in rats and mice. | Arch Toxicol | 1988 | https://conductscience.org/library/papers/3196150 | PubMed |
| 2599802 | Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study. | Invest New Drugs | 1989 | https://conductscience.org/library/papers/2599802 | PubMed |
| 2384306 | Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix. A Gynecologic Oncology Group study. | Invest New Drugs | 1990 | https://conductscience.org/library/papers/2384306 | PubMed |
| 2384305 | Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer. A Gynecologic Oncology Group study. | Invest New Drugs | 1990 | https://conductscience.org/library/papers/2384305 | PubMed |
| 2322987 | Triple combination of retinoic acid plus actinomycin D plus dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2322987 | PubMed |
| 2026491 | Phase II trial of N-methylformamide in patients with metastatic melanoma. | Invest New Drugs | 1991 | https://conductscience.org/library/papers/2026491 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6325001
GET https://conductscience.org/api/papers/v1/6325001/authors